Focused On-demand Library for GPI transamidase component PIG-T

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q969N2

UPID:

PIGT_HUMAN

Alternative names:

Phosphatidylinositol-glycan biosynthesis class T protein

Alternative UPACC:

Q969N2; B2RND5; B7Z3N1; B7Z7I8; E1P622; G8JLF5; Q2NL69; Q7Z3N7; Q9BQY7; Q9BQY8; Q9UJG6; Q9Y2Z5

Background:

The GPI transamidase component PIG-T, also known as Phosphatidylinositol-glycan biosynthesis class T protein, plays a crucial role in the post-translational modification of proteins through the addition of a glycosylphosphatidylinositol (GPI) anchor. This process is essential for the proper localization and function of various proteins on the cell surface.

Therapeutic significance:

PIG-T is implicated in Multiple congenital anomalies-hypotonia-seizures syndrome 3 and Paroxysmal nocturnal hemoglobinuria 2. These associations highlight the protein's potential as a target for therapeutic intervention in these genetic disorders, emphasizing the importance of understanding its biological mechanisms.